Increasing awareness, participation, funding and streamlining communication for MS trials.
18th March, 2014
Results of a Phase III clinical trial for laquinimod, an experimental oral treatment for MS, shows slowing of brain volume loss (atrophy) but limited impact on
7th January, 2014
The NHMRC has warned of the risks for patients seeking unproven stem cell treatments and released a new resource to assist doctors and patients.